Seres Therapeutics (MCRB)
(Real Time Quote from BATS)
$1.15 USD
+0.02 (1.77%)
Updated Sep 23, 2024 11:22 AM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Seres Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 128 | 181 | 291 | 254 | 95 |
Receivables | 9 | 0 | 0 | 9 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 30 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 13 | 13 | 6 | 4 |
Total Current Assets | 175 | 195 | 304 | 269 | 100 |
Net Property & Equipment | 22 | 23 | 18 | 14 | 20 |
Investments & Advances | 1 | 1 | 2 | 51 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 50 | 19 | 13 | 1 | 0 |
Total Assets | 359 | 349 | 355 | 343 | 132 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 17 | 14 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 81 | 60 | 45 | 14 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 4 | 17 | 23 | 26 |
Total Current Liabilities | 99 | 86 | 82 | 46 | 46 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 95 | 92 | 87 | 86 | 94 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 102 | 51 | 25 | 25 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 1 | 12 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 403 | 338 | 223 | 168 | 181 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 933 | 875 | 746 | 723 | 411 |
Retained Earnings | -978 | -865 | -614 | -549 | -460 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -45 | 11 | 132 | 175 | -48 |
Total Liabilities & Shareholder's Equity | 359 | 349 | 355 | 343 | 132 |
Total Common Equity | -45 | 11 | 132 | 175 | -48 |
Shares Outstanding | 129.20 | 124.50 | 91.80 | 91.20 | 70.00 |
Book Value Per Share | -0.35 | 0.09 | 1.43 | 1.92 | -0.69 |
Fiscal Year End for Seres Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 71 | 111 | 128 | 170 | 230 |
Receivables | 19 | 7 | 9 | 17 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 53 | 42 | 30 | 19 | 5 |
Other Current Assets | 6 | 5 | 9 | 9 | 9 |
Total Current Assets | 149 | 165 | 175 | 214 | 251 |
Net Property & Equipment | 18 | 19 | 22 | 24 | 24 |
Investments & Advances | 0 | 1 | 1 | 1 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 51 | 50 | 50 | 20 | 19 |
Total Assets | 322 | 341 | 359 | 368 | 406 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 4 | 9 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 86 | 76 | 81 | 54 | 56 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 8 | 8 | 10 | 4 |
Total Current Liabilities | 108 | 98 | 99 | 79 | 78 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 95 | 95 | 95 | 95 | 95 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 102 | 102 | 102 | 101 | 101 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 3 | 4 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 409 | 401 | 403 | 383 | 384 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 964 | 958 | 933 | 922 | 912 |
Retained Earnings | -1,051 | -1,018 | -978 | -937 | -889 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -87 | -60 | -45 | -15 | 23 |
Total Liabilities & Shareholder's Equity | 322 | 341 | 359 | 368 | 406 |
Total Common Equity | -87 | -60 | -45 | -15 | 23 |
Shares Outstanding | 151.40 | 151.00 | 129.20 | 128.20 | 127.90 |
Book Value Per Share | -0.58 | -0.40 | -0.35 | -0.12 | 0.18 |